Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration

Time: 3:30 pm
day: Day Two


  • Proposed mode of action
  • Preclinical in vivo data in combination with anti-VEGF antibodies and checkpoint inhibitors
  • Clinical data from a randomized phase 2 study in mRCC in combination with sunitinib (VEGFR-TKI) leading to Regenerative Medicine Advanced Therapy Designation by FDA